- Home
- DNTH vs PLYM Comparison
DNTH vs PLYM Comparison
Compare DNTH & PLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- PLYM
- Stock Information
- Founded
- DNTH 2015
- PLYM 2011
- Country
- DNTH United States
- PLYM United States
- Employees
- DNTH N/A
- PLYM N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- PLYM Real Estate Investment Trusts
- Sector
- DNTH Health Care
- PLYM Real Estate
- Exchange
- DNTH Nasdaq
- PLYM Nasdaq
- Market Cap
- DNTH 711.2M
- PLYM 817.0M
- IPO Year
- DNTH N/A
- PLYM 2017
- Fundamental
- Price
- DNTH $23.80
- PLYM $18.01
- Analyst Decision
- DNTH Strong Buy
- PLYM Buy
- Analyst Count
- DNTH 9
- PLYM 8
- Target Price
- DNTH $46.43
- PLYM $24.50
- AVG Volume (30 Days)
- DNTH 203.7K
- PLYM 373.2K
- Earning Date
- DNTH 11-07-2024
- PLYM 02-19-2025
- Dividend Yield
- DNTH N/A
- PLYM 5.33%
- EPS Growth
- DNTH N/A
- PLYM N/A
- EPS
- DNTH N/A
- PLYM 0.01
- Revenue
- DNTH $5,366,000.00
- PLYM $201,569,000.00
- Revenue This Year
- DNTH $98.73
- PLYM N/A
- Revenue Next Year
- DNTH N/A
- PLYM $6.60
- P/E Ratio
- DNTH N/A
- PLYM $976.16
- Revenue Growth
- DNTH 51.41
- PLYM 2.64
- 52 Week Low
- DNTH $8.24
- PLYM $17.22
- 52 Week High
- DNTH $33.77
- PLYM $24.71
- Technical
- Relative Strength Index (RSI)
- DNTH 46.14
- PLYM 39.07
- Support Level
- DNTH $22.59
- PLYM $18.49
- Resistance Level
- DNTH $24.57
- PLYM $19.21
- Average True Range (ATR)
- DNTH 1.49
- PLYM 0.53
- MACD
- DNTH 0.04
- PLYM -0.02
- Stochastic Oscillator
- DNTH 30.84
- PLYM 37.28
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About PLYM Plymouth Industrial REIT Inc.
Plymouth Industrial REIT Inc is a full-service, vertically integrated, self-administered, and self-managed Maryland corporation. It is focused on the acquisition, ownership, and management of single and multi-tenant Class B industrial properties, including distribution centers, warehouses, and light industrial properties, located in secondary and primary markets across the United States. The company has one reportable segment, which is Industrial properties. The majority of its property portfolio is spread across Florida, Ohio, Indiana, Tennessee, Illinois and Georgia, among others. It receives income primarily from the rental revenue through its properties.